Juniper Pharmaceuticals (Nasdaq: JNP) is developing therapeutics that address unmet medical needs in women’s health. Our current pipeline leverages the 505(b)(2) regulatory pathway with new formulations of existing pharmaceuticals.
The Company has a successful history in developing pharmaceutical products, including Crinone® 8% (progesterone gel), which is commercially available in the United States and over 90 countries around the world.
Our current intravaginal ring (IVR) product candidates are: JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women; JNP-0201, a combination estrogen + progesterone IVR for menopausal symptoms; and, JNP-0301, a progesterone IVR for the prevention of preterm birth in women with a short cervical length at mid-pregnancy.
We are leveraging the in-house pharmaceutical development, clinical trial supply manufacturing, and analytical capabilities of Juniper Pharma Services to advance our innovative product pipeline, while also providing valuable intellectual property-related consultative services to our pharmaceutical industry customers.
Juniper is positioned for success with a highly experienced leadership team in combination with a solid balance sheet and strong cash flows to advance a proprietary pipeline for long term value creation.
Crinone® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.